<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K/A
<TABLE>
<C> <S>
/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
</TABLE>
FOR THE FISCAL YEAR ENDED JULY 31, 1999
OR
<TABLE>
<C> <S>
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
</TABLE>
FOR THE TRANSITION PERIOD FROM ______________ TO ______________
COMMISSION FILE NUMBER: 0-27756
------------------------
ALEXION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
<TABLE>
<S> <C>
DELAWARE 13-3648318
(State or Other Jurisdiction (I.R.S. Employer
of Identification No.)
Incorporation or Organization)
</TABLE>
25 SCIENCE PARK, NEW HAVEN, CONNECTICUT 06511
(Address of Principal Executive Offices) (Zip Code)
203-776-1790
(Registrant's telephone number, including area code)
------------------------
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock, par
value $0.0001
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes / / No /X/
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. / /
The aggregate market value of the Common Stock held by non-affiliates of the
registrant, based upon the last sale price of the Common Stock reported on the
National Association of Securities Dealers Automated Quotation (NASDAQ) National
Market System on November 17, 1999, was approximately $148,000,000.
The number of shares of Common Stock outstanding as of November 17, 1999 was
11,331,947.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
PART III
ITEM 11. Executive Compensation.
The following table shows all the cash compensation paid by the Company
as well as certain other compensation paid during the fiscal years indicated to
the Chief Executive Officer of the Company and each of the four other most
highly compensated executive officers of the Company for such period in all
capacities in which they served.
<TABLE>
<CAPTION>
SUMMARY COMPENSATION TABLE
LONG TERM
ANNUAL COMPENSATION COMPENSATION
--------------------------------------------------------------------
FISCAL BASE OTHER OPTIONS
NAME AND PRINCIPAL POSITION YEAR SALARY BONUS COMPENSATION (NUMBER OF SHARES)
--------------------------- ---- ------ ----- ------------ ------------------
<S> <C> <C> <C> <C> <C>
Leonard Bell, M.D. 1999 $275,000 $70,800 $4,167 (1) 40,000
President, Chief Executive 1998 250,000 50,000 3,873 (1) 60,000
Officer, Secretary and Treasurer 1997 213,404 1,983 (1) 150,000
David W. Keiser 1999 $190,460 $50,000 $4,102 (1) 22,500
Executive Vice President and 1998 178,000 30,000 3,788 (1) 25,000
Chief Operating Officer 1997 157,642 29,000 1,892 (1) 25,000
</TABLE>
2
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
Louis A. Matis, M.D. 1999 $180,500 $17,500 17,500
Sr. Vice-President and 1998 165,000 30,000 $4,800 (1) 25,000
Chief Scientific Officer 1997 138,423 25,000 2,400 (1) 22,500
Stephen P. Squinto, Ph.D. 1999 $180,500 $25,000 - 17,500
Sr. Vice-President and 1998 165,000 30,000 - 25,000
Chief Technical Officer 1997 148,460 25,000 - 22,500
James A. Wilkins, Ph.D. 1999 $136,000 $20,000 $4,215 (1) 17,500
Vice-President Process Sciences 1998 120,000 25,000 3,600 (1) 20,000
and Manufacturing 1997 113,500 20,000 1,703 (1) 12,500
</TABLE>
(1) Represents the Company's matching contribution pursuant to its 401(k)
defined contribution plan.
3
<PAGE>
The following table sets forth information with respect to option grants in
1999 to the persons named in the Summary Compensation Table.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
POTENTIAL REALIZED
% OF TOTAL VALUE AT ASSUMED
NUMBER OF OPTIONS ANNUAL RATES OF
SECURITIES GRANTED TO EXERCISE MARKET STOCK PRICE
UNDERLYING EMPLOYEES IN OR PRICE ON APPRECIATION FOR
OPTIONS FISCAL YEAR BASE PRICE DATE OF EXPIRATION OPTION TERM (3)
NAME GRANTED(#)(1) (2) ($/SH) GRANT DATE 5% ($) 10% ($)
- ---- ------------- --- ------ ----- ---- ----- ------ --------
<S> <C> <C> <C> <C> <C> <C> <C>
Leonard Bell, M.D. 40,000 (4) 5.5 $9.50 $9.50 07/27/09 $238,980 $605,622
David W. Keiser 22,500 3.1 9.50 9.50 07/27/09 134,426 340,662
Louis A. Matis, M.D. 17,500 2.4 9.50 9.50 07/27/09 104,554 264,960
Stephen P. Squinto, Ph.D. 17,500 2.4 9.50 9.50 07/27/09 104,554 264,960
James A. Wilkins, Ph.D. 17,500 2.4 9.50 9.50 07/27/09 104,554 264,960
</TABLE>
- ---------------------
(1) Options vest in four equal annual installments commencing on the
anniversary date of the grant unless otherwise indicated.
(2) Based upon options to purchase 494,000 shares granted to all employees
during fiscal 1999
(3) The 5% and 10% assumed rates of appreciation are specified by the rules of
the Securities and Exchange Commission and do not represent the Company's
estimate or projection of the future Common Stock price. There can be no
assurance that any of the values reflected in the table will be achieved.
(4) These options vest in three equal annual installments commencing on the
anniversary date of the grant.
The following table sets forth information with respect to (i) stock
options exercised in 1999 by the persons named in the Summary Compensation Table
and (ii) unexercised stock options held by such individuals at July 31, 1999.
AGGREGATED OPTION EXERCISES
IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF UNEXERCISED VALUE OF UNEXERCISED,
SHARES OPTIONS HELD AT FISCAL IN-THE-MONEY OPTIONS AT
ACQUIRED ON VALUE YEAR END FISCAL YEAR END ($)(1)
-------- ----------------------
NAME EXERCISE (#) REALIZED ($) EXERCISABLEUNEXERCISABLE EXERCISABLEUNEXERCISABLE
---- ------------ ------------ ------------------------ ------------------------
<S> <C> <C> <C> <C> <C> <C>
Leonard Bell, M.D. 0 0 423,750 161,250 $1,618,594 $196,969
David W. Keiser 0 0 125,000 72,500 572,656 100,125
Louis A. Matis, M.D. 0 0 133,750 58,750 681,250 45,313
Stephen P. Squinto, Ph.D. 0 0 123,750 58,750 601,250 45,313
James A. Wilkins, Ph.D. 0 0 60,000 45,000 253,906 38,281
</TABLE>
- ----------------------
(1) Based on the average of the high and low sale price of the Common Stock on
July 31, 1999 of $10.375.
4
<PAGE>
EMPLOYMENT AGREEMENTS
Dr. Leonard Bell, President, Chief Executive Officer, Secretary and
Treasurer of the Company, has a three-year employment agreement with the Company
which expires April 1, 2000. The agreement provides that Dr. Bell will be
employed as the President and Chief Executive Officer of the Company and that
the Company will use its best efforts to cause Dr. Bell to be elected to the
Board of Directors for the term of the agreement. Dr. Bell currently receives an
annual base salary of $283,000. The contract provides that if (i) Dr. Bell is
dismissed for any reason other than cause (as defined in the employment
agreement) or (ii) Dr. Bell terminates the employment agreement for certain
reasons including (a) certain changes in control of the Company, (b) Dr. Bell's
loss of any material duties or authority, (c) if the Chief Executive Officer is
not the highest ranking officer of the Company, (d) an uncured material breach
of the employment agreement by the Company and (e) the retention of any senior
executive officer by the Company, or an offer to pay compensation to any senior
executive of the Company that in either case is unacceptable to Dr. Bell, in his
reasonable judgment, then Dr. Bell shall be entitled to receive a lump sum cash
payment equal to Dr. Bell's annual salary then in effect multiplied by the
number of years remaining in the term of the employment agreement. In addition,
upon such termination, all stock options and stock awards vest and become
immediately exercisable and remain exercisable through their original terms. If,
upon the termination of the employment agreement on April 1, 2000, Dr. Bell
shall cease to be employed by the Company in the capacity of Chief Executive
Officer by reason of the Company's decision not to continue to employ Dr. Bell
as Chief Executive Officer at least on terms substantially similar to those set
forth in the existing employment agreement, then Dr. Bell will be entitled to a
severance payment equal to his annual salary during the final year of such
employment agreement.
Mr. David W. Keiser, Executive Vice-President and Chief Operating
Officer, has a three-year employment agreement with the Company which commenced
in July 1997. Mr. Keiser currently receives an annual base salary of $205,697.
Dr. Stephen P. Squinto, Senior Vice-President and Chief Technical
Officer, has a five-year employment agreement with the Company which commenced
in March 1997. Dr. Squinto currently receives an annual base salary of $187,720.
Dr. Louis A. Matis, Senior Vice President and Chief Scientific Officer,
has a five-year employment agreement with the Company which commenced in August
1997. Dr. Matis currently receives an annual base salary of $187,720.
Dr. James A. Wilkins, Vice-President Process Sciences and
Manufacturing, had a five-year employment agreement with the Company which
commenced in September 1993. Dr. Wilkins receives an annual base salary of
$142,800.
Under the employment agreements for each of Mr. Keiser and Drs. Squinto
and Matis, if any of them, respectively, is dismissed for any reason other than
cause (as defined in the employment agreement), death or disability, or if any
of them, respectively, terminates the employment agreement because of an uncured
material breach thereof by the Company, he shall
5
<PAGE>
be entitled to receive a lump sum cash payment equal to the greater of (a) the
annual salary for the remainder of the then current year of employment and (b)
six months salary at the annual rate for the then current year of employment. In
addition, upon such termination, all stock options shall accelerate vesting such
that the number of such options vested on the day of termination shall be equal
to the number of such options vested if the executive were to have been
continuously employed by the Company until the date twelve months after the date
of termination.
All the Company's employment agreements require acknowledgment of the
Company's possession of information created, discovered or developed by the
employee/executive and applicable to the business of the Company and any client,
customer or strategic partner of the Company. Each employee/executive also
agreed to assign all rights he/she may have or acquire in proprietary
information and to keep such proprietary information confidential and also
agreed to certain covenants not to compete with the Company.
COMPENSATION OF DIRECTORS
Directors may be granted options to purchase Common Stock under the
1992 Stock Option Plan and the 1992 Outside Directors Plan. During February
1996, Drs. Fried, Link and Marks, independent members of the Board and the
members of the Company's audit and compensation committees, became entitled to
receive an annual accrued stipend of $25,000, $8,000 and $8,000, respectively,
which began to accrue on November 1, 1994. Per meeting fees were paid in the
amounts of $1,500, $750, and $750 to Drs. Fried, Link and Marks, respectively.
These per meeting fees were deducted from the accrued stipends, which were paid
during 1996. Effective September 9, 1996, all non-employees, non-Chairman
members of the Board became entitled, with 75% attendance at Board meetings, to
receive an annual accrued stipend of up to $8,000. The Chairman of the Board is
entitled, with 75% attendance at Board meetings, to receive an annual accrued
stipend of up to $25,000. Per meeting fees are paid in the amounts of $1,500 and
$750 to the Chairman of the Board and non-employee members of the Board,
respectively. These per meeting fees are deducted from the maximum annual
accrued stipends, which are to be paid in October of the following year. Each of
Drs. Fried, Madri, Marks, Link, and Ms. More all attended at least 75% of the
meetings of the Company's Board and received their full annual stipend.
The Company's 1992 Outside Directors' Stock Option Plan (the
"Directors' Option Plan") was adopted by the Board of Directors in August 1992
and approved by its stockholders in September 1992. The Directors' Option Plan
was amended in November 1995. The Directors' Option Plan provides for the
automatic grant of options to purchase shares of Common Stock to directors of
the Company who are not officers, nor employees, nor consultants of the Company
or any of its subsidiaries (other than the Chairman of the Board of Directors of
the Company who shall be eligible) ("Outside Directors"). Subject to the
provisions of the Directors' Option Plan, the Board has the power and authority
to interpret the Directors' Plan, to prescribe, amend and rescind rules and
regulations relating to the Directors' Plan and to make all other determinations
deemed necessary or advisable for the administration of the Directors' Option
Plan. No
6
<PAGE>
participant may participate in any determination of the Board concerning options
granted to such Participant under the Directors' Option Plan.
Under the Directors' Option Plan, each Outside Director receives an
option to purchase 7,500 shares of Common Stock on the date of his or her
election to the Board. In addition, on the date of the Annual Meeting and on the
date of each subsequent annual meeting of stockholders at which a director is
reelected, such director, if he or she is still an Outside Director on such date
and has attended, either in person or by telephone, at least seventy-five
percent (75%) of the meetings of the Board of Directors that were held while he
or she was a director since the prior annual meeting of stockholders, will be
granted an option to purchase an additional 2,000 shares of the Company's Common
Stock. All options granted under the Outside Directors' Plan will have an
exercise price equal to the fair market value on the date of grant. Options
granted under the Outside Directors' Plan vest in three equal annual
installments beginning on the anniversary of the date of grant.
COMPENSATION COMMITTEE REPORT TO STOCKHOLDERS
The report of the Compensation Committee shall not be deemed
incorporated by reference by any general statement incorporating by reference
this proxy statement into any filing under the Securities Act of 1933, as
amended (the "Securities Act") or under the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), except to the extent that the Company specifically
incorporates this information by reference, and shall not otherwise be deemed
filed under such Acts.
The Compensation Committee is currently comprised of four directors. As
members of the Compensation Committee, it is our responsibility to determine the
most effective total executive compensation strategy based on the Company's
business and consistent with stockholders' interests. Our specific duties entail
reviewing the Company's compensation practices, recommending compensation for
executives and key employees, the making of recommendations to the Board of
Directors with respect to major compensation and benefit programs, and
administering the Company's stock option plans.
COMPENSATION PHILOSOPHY
The Company's overall compensation philosophy is to offer competitive
salaries, cash incentives, stock options and benefit plans consistent with the
Company's financial position. Rewarding capable employees who contribute to the
continued success of the Company plus equity participation and a strong
alignment to stockholder's interests are key elements of the Company's
compensation policy. One of the, Company's strengths contributing to its success
is the strong management team - many of whom have been with the Company for a
significant period of time. The Company's executive compensation policy is to
attract and retain key executives necessary for the Company's short and
long-term success by establishing a direct link between executive compensation
and the performance of the Company by rewarding individual initiative and the
achievement of annual corporate goals through salary and cash bonus awards;
7
<PAGE>
and by providing equity awards based upon present and expected future
performance to allow executives to participate in maximizing shareholder value.
In awarding salary increases and bonuses, the Compensation Committee
did not relate the various elements of corporate performance to each element of
executive compensation. Rather, the Compensation Committee considered whether
the compensation package as a whole adequately compensated each executive for
the Company's performance during the past year and executive's contribution to
such performance.
Under the Omnibus Budget Reconciliation Act ("OBRA") which was enacted
in 1993, publicly held companies may be prohibited from deducting as an expense
for federal income tax purposes total remuneration in excess of $1 million paid
to certain executive officers in a single year. However, OBRA provides an
exception for "performance based" remuneration, including stock options. The
Company expects to keep "nonperformance based" remuneration within the $1
million limit in order that all executive compensation will be fully deductible.
Nevertheless, although the Committee considers the net cost to the Company in
making all compensation decisions (including, for this purpose, the potential
limitation on deductibility of executive compensation), there is no assurance
that compensation realized with respect to any particular award will qualify as
"performance based" remuneration.
BASE SALARY
Base salary represents the fixed component of the executive
compensation program. The Company's philosophy regarding base salaries is
conservative, maintaining salaries at approximately competitive industry
average. Determinations of base salary levels are established on an annual
review of marketplace competitiveness with similar biopharmaceutical companies,
and on internal relationships. Periodic increases in base salary relate to
individual contributions to the Company's overall performance, relative
marketplace competitiveness levels, length of service and the industry's annual
competitive pay practice movement. No specific performance targets were
established for fiscal year 1998, which was the base year for determining the
salary increase's awarded during 1999. In determining appropriate levels of base
salary, the Compensation Committee relied in part on several biopharmaceutical
industry compensation surveys.
BONUS
Bonuses represent the variable component of the executive compensation
program that is tied to the Company's performance and individual achievement.
The Company's policy is to base a significant portion of its senior executives'
cash compensation on bonus. In determining bonuses, the Compensation Committee
considers factors such as relative performance of the Company during the year
and the individual's contribution to the Company's performance.
STOCK OPTIONS
8
<PAGE>
The Compensation Committee, which administers the Company's stock
option plans, believes that one important goal of the executive compensation
program should be to provide executives, key employees and consultants - who
have significant responsibility for the management, growth and future success of
the Company with an opportunity to increase their ownership and potentially gain
financially from the Company's stock price increases. This approach ensures that
the best interests of the stockholders, executives and employees will be closely
aligned. Therefore, executive officers and other key employees of the Company
are granted stock options from time to time, giving them a right to purchase
shares of the Company's Common Stock at a specified price in the future. The
grant of options is based primarily on an employee's potential contribution to
the Company's growth and financial results. In determining the size of option
grants, the Compensation Committee considers the number of options owned by such
employee, the number of options previously granted and currently outstanding,
and the aggregate size of the current option grants. Options generally are
granted at the prevailing market value of the Company's Common Stock and will
only have value if the Company's stock price increases. Generally, grants of
options vest in equal amounts over four years and the individual must be
employed by the Company for such options to vest.
1999 COMPENSATION TO CHIEF EXECUTIVE OFFICER
In reviewing and recommending Dr. Bell's salary and bonus and in
awarding him stock options for fiscal year 1999 and for his future services, the
Compensation Committee followed its compensation philosophy. Dr. Bell's annual
salary was increased to $283,000 in August 1999. For the 1999 fiscal year, Dr.
Bell did earn a $70,000 bonus, which was paid in August 1999. The Compensation
Committee recommended this salary and bonus in recognition of Dr. Bell's
achievements in entering into an exclusive collaboration with Procter & Gamble,
advancing the Company's research efforts, and advancing the Company's clinical
progress. In 1999, Dr. Bell was granted options, to purchase 40,000 shares of
the Company's Common Stock at an exercise price of $9.50, the fair market value
on the date of grant, under the terms of the 1992 Stock Option Plan. The options
will become exercisable in equal installments over three years on the
anniversary date of the date of grant. The Compensation Committee recommended
this option grant, to secure the long-term services of the Company's chief
executive officer and to further align the chief executive officer's
compensation with stockholder interests.
COMPENSATION COMMITTEE
JOHN H. FRIED, PH.D., MAX LINK, PH.D., LEONARD MARKS, JR., PH.D. AND ALVIN S.
PARVEN
9
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(A) (1) FINANCIAL STATEMENTS:
The financial statements required by this item are submitted in a separate
section beginning on page F-1 of this report.
(2) FINANCIAL STATEMENT SCHEDULES:
Schedules have been omitted because of the absence of conditions under which
they are required or because the required information is included in the
financial statements or notes thereto.
(3) EXHIBITS:
<TABLE>
<C> <S>
3.1 Certificate of Incorporation, as amended.*(1)
3.2 Bylaws.*(1)
4.1 Specimen Common Stock Certificate.*(1)
10.1 Employment Agreement, dated April 1, 1997, between the
Company and Dr. Leonard Bell.*(2)
10.2 Employment Agreement, dated October 22, 1997, between the
Company and David W. Keiser.*(3)
10.3 Employment Agreement, dated October 22, 1997, between the
Company and Dr. Stephen P. Squinto.*(3)
10.4 Employment Agreement, dated October 22, 1997, between the
Company and Dr. Louis A. Matis.*(3)
10.5 Employment Agreement, dated July 1993, between the Company
and Dr. James A. Wilkins, as amended.*(1)
10.6 Administrative Facility Lease, dated August 23, 1995,
between the Company and Science Park Development
Corporation.*(1)
10.7 Research and Development Facility Lease, dated August 23,
1995, between the Company and Science Park Development
Corporation.*(1)
10.8 Option Agreement, dated April 1, 1992 between the Company
and Dr. Leonard Bell.*(1)
10.9 Company's 1992 Stock Option Plan, as amended.*(4)
10.10 Company's 1992 Stock Option Plan for Outside Directors, as
amended.*(5)
10.11 Form of Investor Rights Agreement, dated December 23, 1994,
between the Company and the purchasers of the Company's
Series A Preferred Stock, as amended.*(1)
10.12 Exclusive License Agreement dated as of June 19, 1992 among
the Company, Yale University and Oklahoma Medical Research
Foundation.*(1)+
10.13 License Agreement dated as of September 30, 1992 between the
Company and Yale University, as amended July 2, 1993.*(1)+
10.14 License Agreement dated as of August 1, 1993 between the
Company and Biotechnology Research and Development
Corporation ("BRDC"), as amended as of July 1, 1995.*(1)+
10.15 License Agreement dated January 25, 1994 between the Company
and The Austin Research Institute.*(1)+
</TABLE>
10
<PAGE>
<TABLE>
<C> <S>
10.16 Exclusive Patent License Agreement dated April 21, 1994
between the Company and the National Institutes of
Health.*(1)+
10.17 License Agreement dated July 22, 1994 between the Company
and The Austin Research Institute.*(1)+
10.18 License Agreement dated as of January 10, 1995 between the
Company and Yale University.*(1)+
10.19 Advanced Technology Program ("ATP"), Cooperative Agreement
70NANB5H, National Institute of Standards and Technology,
entitled "Universal Donor Organs for Transplantation," dated
September 15, 1995.*(1)+
10.20 U.S. Department of Health and Human Services, National
Heart, Lung and Book Institute, Small Business Research
Program, Phase II Grant Application, entitled "Role of
Complement Activation in Cardiopulmonary Bypass," dated
December 14, 1994; and Notice of Grant Award dated September
21, 1995.*(3)+
10.21 Agreement to be Bound by Master Agreement dated as of August
1, 1993 between the Company and BRDC.*(1)
10.22 Research and Development Facility Lease, dated April 1,
1996, between the Company and Science Park Development
Corporation.*(6)
10.23 License Agreement dated March 27, 1996 between the Company
and Medical Research Council.*(6)+
10.24 License Agreement dated May 8, 1996 between the Company and
Enzon, Inc.*(6)+
10.25 Stock Purchase Agreement dated September 8, 1997 by and
between the Company and Biotech Target S.A. *(7)+
10.26 Stock Purchase Agreement dated March 4, 1998 by and between
the Company and Biotech Target S.A. *(7)+
10.27 Asset Purchase Agreement dated as of February 9, 1999
between the Company and United States Surgical Corporation.*(8)
10.28 Collaboration Agreement dated January 25, 1999 between the
Company and The Procter & Gamble Company, as amended.*(8)+
10.29 Letter agreement dated September 14, 1999 between the
Company and Leonard Bell.*(8)
23.1 Consent of Arthur Andersen LLP.*(8)
27.1 Financial Data Schedule.*(8)
99.1 Risk Factors.*(8)
</TABLE>
- ------------------------
* Previously filed.
(1) Incorporated by reference to the Company's Registration Statement on
Form S-1 (Reg. No. 333-00202).
(2) Incorporated by reference to the Company's Amendment No. 1 to Registration
Statement on Form S-1 (Reg. No. 333-19905) filed on April 4, 1997.
(3) Incorporated by reference to the Company's Annual Report on Form 10-K for
the fiscal year ended July 31, 1997.
(4) Incorporated by reference to the Company's Registration Statement on
Form S-8 (Reg. No. 333-71879) filed on February 5, 1999.
11
<PAGE>
(5) Incorporated by reference to the Company's Registration Statement on
Form S-8 (Reg. No. 333-71985) filed on February 8, 1999.
(6) Incorporated by reference to the Company's Annual Report on Form 10-K for
the fiscal year ended July 31, 1996.
(7) Incorporated by reference to the Company's Annual Report on Form 10-K for
the fiscal year ended July 31, 1998.
(8) Incorporated by reference to the Company's Annual Report on Form 10-K for
the fiscal year ended July 31, 1999.
+ Confidential treatment was granted for portions of such document.
(B) REPORTS ON FORM 8-K:
Current Report on Form 8-K dated May 25, 1999 relating to the election of
Alvin S. Parven to the Company's Board of Directors.
(C) EXHIBITS:
See (a) (3) above.
(D) FINANCIAL STATEMENT SCHEDULES:
See (a) (2) above.
12
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this amended report to be
signed on its behalf by the undersigned, thereunto duly authorized.
<TABLE>
<S> <C> <C>
ALEXION PHARMACEUTICALS, INC.
By: /s/ LEONARD BELL
-----------------------------------------
Leonard Bell, M.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER,
SECRETARY AND TREASURER
</TABLE>
13
